Equillium (EQ) 12th Annual Cantor Fitzgerald Global Healthcare Conference summary

Program overview and strategic direction

• Lead molecule EQ504, an aryl hydrocarbon receptor (AhR) modulator, was acquired in 2024 and announced in May 2025, with strong financial backing and recent $35M investment.

• EQ504 is positioned for both anti-inflammatory and wound-healing effects, targeting high unmet needs, with ulcerative colitis (UC) as the lead indication.

• Formulation work completed for colon-targeted delivery in UC and nebulized delivery for lung indications, minimizing systemic exposure.

• Regulatory submission to Australian authorities is complete, with first patient dosing as a milestone for additional financing and top-line data expected six months post-study initiation.

• Expansion into lung and potential upper GI indications is planned, with future consideration for Crohn’s and celiac disease based on emerging data.

Scientific insights and differentiation

• EQ504 was designed from the ITE scaffold for high selectivity, potency, and drug-like properties, aiming for best-in-class status.

• Preclinical studies show EQ504 induces miR-124 via AhR activation, primarily in immune cells, with broader modulation of immune and epithelial pathways.

• Epithelial cell activity is highlighted as critical for efficacy in UC, supporting both immune modulation and tissue repair.

• Phase I study in healthy volunteers will assess safety, PK/PD, and local target engagement in the colon to inform dose selection for phase II.

• EQ504’s solubility and permeability enable both GI and inhaled delivery, differentiating it from less soluble competitors like indirubin-based programs.

Competitive landscape and safety considerations

• EQ504 is compared favorably to other AhR modulators, including indirubin prodrugs and obefazimod, with advantages in potency, solubility, and targeted delivery.

• Indigo naturalis provides proof of concept for AhR modulation but lacks dose control and regulatory rigor for drug development.

• Safety profile is supported by extensive preclinical genotoxicity testing, with no carcinogenicity signals observed to date.

• Non-melanoma skin cancer signals seen with obefazimod are not attributed to AhR modulation per se, and targeted delivery is expected to further mitigate risk.

• Future development will be guided by emerging clinical data in UC, Crohn’s, and lung diseases, with a focus on maximizing efficacy and safety through precise tissue targeting.